DRG 837 Overview

DRG 837 covers hospital inpatient cases involving chemotherapy where acute leukemia is listed as a secondary diagnosis or where a high dose chemotherapy agent is administered and a Major Complication or Comorbidity is present. This Diagnosis-Related Group captures resource intensity associated with complex chemotherapy management, higher toxicity monitoring, and complications requiring inpatient care. It matters for Medicare payment because cases classified to this DRG typically have higher relative weights and reimbursement to reflect the added clinical complexity and resource use. Accurate coding of diagnoses, procedures, and Major Complication or Comorbidity status drives correct assignment and payment under Medicare.

• Acute inpatient chemotherapy optimization studies: trials focusing on protocols for delivering intensive induction or consolidation chemotherapy to hospitalized patients with acute leukemia as a secondary diagnosis or receiving high-dose chemotherapy agents. These studies enroll patients during the acute inpatient phase to compare dosing strategies, supportive care bundles (e.g., antimicrobial prophylaxis timing, transfusion triggers, and growth factor use), and management of immediate toxicities such as febrile neutropenia or mucositis. Results inform clinicians and hospital administrators about best practices that can reduce length of stay, prevent ICU transfers, and lower complication-driven costs relevant to DRG 837 reimbursements.
• Comparative effectiveness and safety studies of high-dose chemotherapy regimens in medically complex patients: observational cohorts or pragmatic randomized trials evaluating different high-dose chemotherapy approaches in patients who have significant comorbidities, prior malignancies, or treatment-related organ dysfunction and who therefore qualify for this DRG. These studies measure treatments’ relative efficacy, adverse event profiles, and resource utilization (transfusion needs, inpatient days, readmissions), helping payers and providers assess which regimens yield acceptable clinical benefit while minimizing high-cost complications in a high-risk inpatient population.
• Post-discharge outcomes and care transitions research: prospective studies examining short- and medium-term outcomes after hospital discharge following intensive chemotherapy episodes, including readmission rates, infection-related complications, outpatient supportive care needs, and patient-reported functional status. This research targets patients classified under DRG 837 to identify predictors of early readmission and to test interventions such as structured discharge planning, early outpatient follow-up, or home-based nursing support; findings are directly relevant for value-based payment models and for designing discharge pathways that reduce costly rehospitalizations.